Arrowhead Pharmaceuticals (NASDAQ: ARWR) Price Target Raised Amid Strong Plozasiran Trial Results

• Chardan Capital raised its price target for Arrowhead Pharmaceuticals (NASDAQ: ARWR) to $115, indicating a potential 26.33% upside for the biotechnology stock.
• The company's investigational drug, plozasiran, demonstrated strong efficacy in late-stage trials, significantly lowering triglyceride levels for patients with severe hypertriglyceridemia (sHTG).
• Despite a 21.91% stock surge and a new 52-week high following the positive trial news, GuruFocus suggests the stock is "Significantly Overvalued" with a GF Value of $49.98.

Arrowhead Pharmaceuticals (NASDAQ: ARWR) is a leading biotechnology company dedicated to developing innovative medicines to treat serious diseases. On July 22, 2026, Chardan Capital analyst Keay Nakae increased the firm's price target on Arrowhead Pharmaceuticals to $115. This new target suggests a potential upside of about 26.33% from the stock's price of $91.03 at the time, offering an optimistic outlook for this biotech investment.

The analyst's positive outlook follows the company's successful trial results for its groundbreaking drug, plozasiran. This drug is specifically designed to treat severe hypertriglyceridemia (sHTG), a critical condition characterized by very high levels of blood fats called triglycerides, which significantly increases the risk of serious health problems like pancreatitis.

The late-stage SHASTA-3 and SHASTA-4 clinical trials for plozasiran met their main goal of lowering triglyceride levels compared to a placebo, showcasing the drug's potential in the healthcare sector. The studies also successfully achieved all secondary goals. Patients receiving a quarterly 25 mg dose saw a median triglyceride decrease of an impressive 79%, demonstrating plozasiran's strong effectiveness in managing sHTG.

As highlighted by Seeking Alpha, these robust results position plozasiran to challenge competitors like Ionis's Tryngolza. Its convenient quarterly dosing and strong safety profile are considered key advantages in the competitive drug development landscape. Following the news of the successful trials, Arrowhead Pharmaceuticals' stock price surged 21.91% to $90.85, hitting a new 52-week high of $95.49 during the day's trading, reflecting strong market confidence.

However, according to GuruFocus, the stock's GF Value is $49.98, which suggests Arrowhead Pharmaceuticals is currently "Significantly Overvalued." This provides a different perspective on the company's current market price compared to the analyst's optimistic target, prompting investors to consider the stock's valuation. The company plans to file for regulatory approval of the drug before the end of the year, a crucial step for its commercialization.